NASDAQ:BBHVanEck Vectors Biotech ETF Stock Price, Forecast & News

VanEck Vectors Biotech ETF's stock was trading at $126.82 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, BBH shares have increased by 26.4% and is now trading at $160.33. View which stocks have been most impacted by Coronavirus.

News stories about BBH stock have been trending very positive on Tuesday, InfoTrie Sentiment reports. The research group identifies positive and negative media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. VanEck Vectors Biotech ETF earned a media sentiment score of 3.5 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news aboutVanEck Vectors Biotech ETF.

Some companies that are related to VanEck Vectors Biotech ETF include Adams Diversified Equity Fund (ADX), PIMCO Corporate&Income Opportunity Fund (PTY), Tri-Continental (TY), Hercules Capital (HTGC), Gabelli Equity Trust (GAB), Royce Value Trust (RVT), Liberty All-Star Equity Fund (USA), Tortoise Energy Infrastructure (TYG), Boulder Growth & Income Fund (BIF), Tekla Healthcare Investors (HQH), AllianceBernstein Global Hgh Incm Fd (AWF), Blackrock Muniyield Insured Fund (MYI), Invesco Van Kampen Munpl Oprtnty Tr (VMO), General American Investors (GAM) and Templeton Global Income Fund (GIM). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other VanEck Vectors Biotech ETF investors own include Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Marina Biotech (MRNA), Sanofi (SNY), Cidara Therapeutics (CDTX), Quest Diagnostics (DGX), Crispr Therapeutics (CRSP), Johnson & Johnson (JNJ), Matinas BioPharma (MTNB) and Micron Technology (MU).

VanEck Vectors Biotech ETF trades on the NASDAQ under the ticker symbol "BBH."

VanEck Vectors Biotech ETF's stock is owned by a number of institutional and retail investors. Top institutional investors include Morgan Stanley (1.67%), Morgan Stanley (1.56%), UBS Group AG (1.71%), Murphy Capital Management Inc. (1.38%), Mogy Joel R Investment Counsel Inc. (0.83%) and Envestnet Asset Management Inc. (0.58%).

BBH stock was sold by a variety of institutional investors in the last quarter, including Raymond James & Associates, Bank of New York Mellon Corp, Mogy Joel R Investment Counsel Inc., Ironsides Asset Advisors LLC, UBS Group AG, Murphy Capital Management Inc., Aspiriant LLC, and Wells Fargo & Company MN.

BBH stock was acquired by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc., Columbus Macro LLC, PNC Financial Services Group Inc., Advisor Group Holdings Inc., CIBC World Markets Inc., CAPROCK Group Inc., Cambridge Investment Research Advisors Inc., and HighTower Advisors LLC.

Shares of BBH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of BBH stock can currently be purchased for approximately $160.33.

VanEck Vectors Biotech ETF has a market capitalization of $464.48 million.